Equities

Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)217.55
  • Today's Change-1.10 / -0.50%
  • Shares traded162.00k
  • 1 Year change+10.88%
  • Beta1.3752
Data delayed at least 15 minutes, as of May 17 2024 06:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.

  • Revenue in INR (TTM)1.07bn
  • Net income in INR-3.63bn
  • Incorporated2006
  • Employees407.00
  • Location
    Sun Pharma Advanced Research Co Ltd17B Mahal Industrial EstateMahakali Caves Road, Andheri (East)MUMBAI 400093IndiaIND
  • Phone+91 2 266455685
  • Fax+91 2 266455685
  • Websitehttps://www.sparc.life/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Unichem Laboratories Ltd16.75bn145.69m38.74bn3.12k266.29--29.722.312.072.07234.69--------5,364,373.00---1.38---1.6659.9456.150.8696-3.60---0.9613----5.7610.51-711.67---22.60--
Advanced Enzyme Technologies Ltd6.24bn1.33bn42.49bn338.0031.853.2124.676.8111.9311.9355.83118.410.42191.066.27--9.2610.8210.2311.9376.8372.8121.9524.596.2257.810.033415.1715.398.2626.193.7227.8553.42
Aarti Drugs Ltd25.29bn1.71bn44.16bn1.50k25.813.4519.801.7518.6118.61274.44139.401.043.353.22--7.079.7310.9815.7433.6524.966.798.251.057.910.3056---6.9010.133.0713.8224.96--
Shilpa Medicare Ltd11.23bn-6.71m50.72bn1.03k----47.704.52-0.0714-0.0714131.44--------10,873,050.00--3.89--4.9264.4260.22-0.05389.29--1.16--10.65-8.335.82-153.54--14.58--
Aarti Pharmalabs Ltd18.53bn2.17bn53.20bn1.40k24.533.0318.342.8723.9423.94204.45193.890.76981.643.86--9.01--12.30--44.90--11.71--1.0118.170.1397---4.76--12.10------
Orchid Pharma Ltd8.12bn1.25bn55.73bn838.0038.55--35.066.8628.5026.84175.33--------9,691,729.00---1.07---1.9641.4945.8715.63-3.52--4.34----19.00-0.6456187.87--68.72--
Blue Jet Healthcare Ltd-100.00bn-100.00bn63.17bn--------------------------------------------------5.49---11.88------
Sun Pharma Advanced Research Co Ltd1.07bn-3.63bn70.55bn407.00------66.13-11.22-11.223.29--------2,621,133.00---59.13---119.2975.2179.70-340.66-116.46---400.34----73.9825.00-9.43---13.96--
F D C Ltd19.16bn2.90bn74.08bn6.37k25.82--22.543.8717.6317.63116.59--------3,006,457.00--11.68--13.2965.7262.0315.1115.85--70.61--1.2216.7410.49-10.342.2625.03--
Marksans Pharma Ltd21.03bn3.17bn74.70bn1.40k23.39--19.303.557.057.0546.71--------15,024,090.00--14.78--19.5851.8850.1615.2113.01--44.45--5.4924.2315.2044.2951.896.6158.49
Procter & Gamble Health Ltd11.69bn2.14bn79.49bn1.41k37.16--33.026.80128.85128.85703.49--------8,305,331.00--------70.45--18.31----400.33----10.34--19.19------
Neuland Laboratories Ltd.15.59bn3.00bn80.06bn1.57k26.686.2422.255.14233.89233.891,214.80999.780.91352.334.24--17.599.2523.5812.7152.9247.2119.2511.991.3328.780.06927.1330.8418.5183.5178.7617.8863.45
Strides Pharma Science Ltd39.53bn-1.52bn80.44bn2.85k----135.992.03-16.88-10.96436.72--------13,871,790.00---0.9448---1.5958.9049.75-4.37-2.19--0.9061----20.135.3351.93---25.10-5.59
Wockhardt Ltd27.76bn-5.01bn83.41bn2.74k------3.00-34.79-34.79192.79--------10,131,390.00---4.12---7.3457.6053.98-19.16-10.98---0.1981-----17.93-7.60-129.10---7.43--
Granules India Ltd45.26bn3.95bn96.17bn3.65k24.32--16.082.1216.3216.32186.88--------12,400,240.00--11.15--16.5551.9449.358.7312.39--6.53--10.0819.8421.6725.1631.26-1.668.45
Glenmark Life Sciences Ltd22.83bn4.71bn100.63bn1.82k21.404.3119.194.4138.3838.38186.08190.350.82241.582.90--16.9618.2820.4330.0356.1153.4020.6220.232.85401.550.0073--5.6420.830.84119.2169.11--
Data as of May 17 2024. Currency figures normalised to Sun Pharma Advanced Research Co Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

1.79%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 20242.32m0.72%
BlackRock Fund Advisorsas of 04 Apr 20241.72m0.53%
Norges Bank Investment Managementas of 31 Dec 2023620.84k0.19%
SSgA Funds Management, Inc.as of 04 Apr 2024425.63k0.13%
BlackRock Advisors (UK) Ltd.as of 02 Apr 2024361.64k0.11%
Samco Asset Management Pvt. Ltd.as of 30 Apr 2024139.09k0.04%
TIAA-CREF Investment Management LLCas of 31 Mar 202460.59k0.02%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 202459.05k0.02%
ITI Asset Management Ltd. (India)as of 30 Apr 202453.24k0.02%
Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 202438.48k0.01%
More ▼
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.